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Background: The two most common interventions for Posttraumatic Stress Disorder (PTSD) are pharmacological
treatment with SSRIs such as paroxetine and psychological treatment such as Trauma-Focused Cognitive Behavioral
Therapy (TF-CBT). International guidelines recommend trauma-focused psychological interventions for all PTSD
patients as first-line treatment (NICE). However, no clear-cut evidence is available to support this recommendation.
Methods/design: In order to compare pharmacological treatment (paroxetine) and psychological treatment
(TF-CBT) in (cost-) effectiveness on the short and the long term, we will randomize 90 patients with chronic PTSD
to either paroxetine (24 weeks) or TF-CBT (10–12 weeks). We will assess symptom severity and costs before and
after the intervention with the Clinician Administered PTSD Scale (CAPS), the Clinical Global Impression Scale (CGI)
and the Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness (TiC-P).
Discussion: This study is unique for its direct comparison of the most commonly used psychological intervention
(TF-CBT) and pharmacological intervention (paroxetine) on (cost-) effectiveness on the short and the long term.
The anticipated results will provide relevant evidence concerning long-term effects and relapse rates and will be
beneficial in reducing societal costs. It may also provide information on who may benefit most from which type of
intervention. Some methodological issues will be discussed.
Trial Registration: Dutch Trial registration: NTR2235
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Approximately 80% of the Dutch population experiences
at least one traumatic event during lifetime [1]. The risk
for development of PTSD after psychological trauma is
approximately 10% in the Netherlands [1] as well as in
other countries like the US [2]. Higher rates in women
than in men have been found in the general population,
e.g. 12% versus 4.6% [1,3-5]. PTSD generally continues
for long periods of time, with a median time to recovery* Correspondence: a.r.polak@amc.nl
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reproduction in any medium, provided the orin the range of 3 to 5 years [2]. The high chronicity, se-
verity, and co morbidity of PTSD are associated with
high levels of functional and psychosocial disability [6],
but also with high health care costs and economic im-
pact due to health care utilization and negative effect on
personal income [7]. Several effective treatments, how-
ever, are available to reduce symptoms and lower these
costs.
At present, pharmacological treatment with selective
serotonin reuptake inhibitors (SSRIs) and psychological
treatment with trauma-focused behavioral therapy, i.e.
Trauma-Focused Cognitive Behavioral Therapy (TF-
CBT) or Eye Movement Desensitisation and Reproces-
sing (EMDR) are recommended for treatment of PTSDtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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controlled trials [10-12] and meta-analyses [13,14],
which demonstrate that these psychological treatments
are effective in treating PTSD symptoms. Selective sero-
tonin reuptake inhibitors (SSRIs) such as paroxetine
[15,16], sertraline [17,18] and fluoxetine [19-21] have
shown favorable results in placebo-controlled rando-
mized clinical trials. The effectiveness of these SSRIs has
also been confirmed in a meta-analysis [22] and sup-
ported by reviews [23,24]. Notwithstanding the evidence
coming from these guidelines and clinical trials, the
choice of treatment in common clinical practice is rather
arbitrary and seems to partly depend on indirect and dir-
ect assumptions of the clinician, style of health service
delivery and patient factors (e.g. [25]). Mellman et al.
[26] estimated that in a community-based sample, 77%
of the PTSD patients received pharmacotherapy. The
preference for pharmacotherapy may be due to the
relatively poorer availability and accessibility of trauma-
focused behavioral therapy, because of more time-
consuming procedures such as referral, waiting list
problems and the short handedness of behavior thera-
pists. Little is known, however, about the difference in
effectiveness between pharmacological versus psycho-
logical treatments.
The only meta-analysis that systematically compared
effect sizes of both psychotherapeutic and pharmaco-
logical treatments for PTSD showed a slight advantage
of CBT compared to other treatments on observer-
related total PTSD symptoms [27]. Caution is, however,
required when comparing effect sizes of pharmacological
to psychotherapy trials as in pharmacological trials with
placebo comparison control, non-specific attentional
effects may have a more modest impact than in psycho-
logical therapy trials with waiting list controls [9]. Some
studies compared the effectiveness of pharmacotherapy
and trauma-focused therapy directly, suggesting a better
long-term outcome for trauma-focused therapy than
pharmacotherapy. One study [28] found relapse of PTSD
symptoms at 6 months follow-up in the paroxetine
group but not in the CBT group, and another study [11]
revealed 58% asymptomatic patients 6 months after the
trauma-focused psychological therapy group, compared
to none in the SSRI group. However, these studies are
rather small (respectively N=21 and N=88) and long-
term consolidation of more than 6 months follow-up of
the effects of pharmacological treatment were not yet
reported. Therefore, several important questions regard-
ing effectiveness, duration of treatment and relapse rates
remain unanswered. Placebo-controlled studies that
investigated treatment duration indicate beneficial
effects of more sustained treatment. Martenyi et al. [29]
have found a 16.1% relapse rate in 12-week fluoxetine
treatment, compared to 5.8% in 24-week fluoxetinetreatment. Furthermore, a study of Londborg et al. [30]
showed that more than half of 41% non-responders after
short-term treatment of 12 weeks achieved responder
status during prolonged treatment of at least 24 weeks
with SSRIs. Other studies have shown that treatment
continuation for more than 24 weeks does not further
reduce the PTSD symptoms but yields lower relapse
rates than placebo [31,32]. These findings support the
notion that a short-term course of treatment with SSRIs
may be inadequate [33].
The importance of an adequately powered and
designed trial determining whether trauma-focused psy-
chological interventions differ from pharmacological
interventions in terms of effectiveness and cost-
effectiveness was already emphasized by national and
international guidelines [8,9]. Gaining more knowledge
on treatments and the consolidation of treatment effects
will not only be beneficial for PTSD patients but may
also reduce societal costs. Therefore we will compare
pharmacological treatment with paroxetine and psycho-
logical treatment with TF-CBT in PTSD. We choose to
compare these particular treatments as up to now, the
majority of the empirical literature on psychotherapies
for PTSD has focused on TF-CBT and this is repeatedly
shown to be effective (e.g. [14,34,35]). Furthermore, par-
ticularly the SSRI paroxetine has proven to be effective
in the reduction of symptoms from all three PTSD
symptom clusters: re-experiencing, hyperarousal and
avoidance [15,16] and has shown to be more effective
than sertraline and fluoxetine in reducing PTSD symp-
tom severity [23].
Research aims and hypotheses
The aim of the proposed study is to compare the
effectiveness and cost-effectiveness of Trauma-Focused
Cognitive Behavioral Therapy (TF-CBT) to paroxetine in
patients with PTSD in a randomized controlled trial in
terms of PTSD symptom reduction. Secondary outcome
measures include general measures of psychological
wellbeing (i.e. anxiety and depression), quality of life,
and related costs. Furthermore, we will take into account
treatment responses by gender, age, and socio-economic
status (incl. ethnic and cultural background) as previous
studies show that women are twice as likely as men to
develop PTSD during their lifetime [2] and indicate that
different psychobiological mechanisms may play a role
in the development of PTSD in women compared to
men [5].
Based on previous findings of the effects of both treat-
ments on clinical symptomatology over time, we expect
the TF-CBT treatment to be more effective in PTSD
symptom reduction than paroxetine most prominently at
long-term follow-up, i.e. several months or years after ces-
sation of both treatments. Furthermore, we hypothesize
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expected relapse rates in comparison with pharmaco-
logical treatment. We will take into account direct medical
costs (health care utilization as well as to inpatient and
outpatient mental health care, day-treatment and primary
physician care), direct non-medical costs (travel to and
from health care providers, out-of-pocket costs) and indir-
ect costs (lost productivity due to sick leave).
Methods/design
The study is funded by the Netherlands Organization
for Health Research and Development (ZonMw,
grant no. 80-82310-98-09034). The study has been
approved by the medical ethical board of the Aca-
demic Medical Center (AMC) (registration no: 09/
080) and is conducted in accordance with the princi-
ples of the Declaration of Helsinki. The trial has been
registered in the Dutch trial register and can be
found at http://www.trialregister.nl (NTR2235).
Study design
The study is designed as a randomized controlled trial
comparing TF-CBT and paroxetine treatment. The
randomization and allocation procedure will be per-
formed by a researcher who has no further role in data
collection. The study design was set up with one pre-
treatment assessment and four post-treatment assess-
ments (at 1 week, 6 months, 12 months and 18 months)
but before starting data-collection the authors added an
assessment at 3 months as well (see Figure 1). All assess-
ments will be performed by research workers blinded for
the allocated treatment. The study will be performed at
the department of psychiatry of the Academic Medical
Center (AMC) in Amsterdam. Patients will be recruited
over the course of 3 years, starting November 2009.
Participants
Our study population will consist of patients with PTSD
that are referred to the outpatient psychiatric clinic of
the AMC. Inclusion criteria are: patients that fulfill all
criteria for a diagnosis of chronic PTSD based on the
DSM-IV [36], have a score of 45 or higher on the
Clinician Administered PTSD Scale (CAPS [37]) 18
years of age or older, give written informed consent and
are eligible for exposure therapy. Exclusion criteria are:
suicidal risk; presence of any of the following DSM-IV
diagnoses: psychotic disorder incl. schizophrenia, a bipo-
lar disorder, depression with psychotic features, or ex-
cessive substance related disorder over the past 2
months, a primary diagnosis of severe depressive dis-
order; an organic disorder that interferes with either TF-
CBT or paroxetine treatment; intolerance to paroxetine
or any other SSRI; taking psychotropic medications that
interact with paroxetine or no mastery of Dutch,English, Turkish or Arabic. Furthermore, female patients
of childbearing potential must have a negative pregnancy
test. Patients will receive a reimbursement that acknowl-
edges the participants’ time and effort (15€ for each
measurement as well as travel expenses).
Sample Size
Sample size calculation
To compare the effectiveness of both interventions, the
difference in CAPS scores between the two groups will
be analyzed. We expect differences in effectiveness and
cost-effectiveness between both treatments to be most
prominent at follow-up, i.e. 6 months, 12 and 18 months
after cessation of the 12-week treatment periods and
therefore sample size calculations should ideally be
based on expected differences at follow-up. However,
due to very few data available for long-term power cal-
culations, we initially choose to be conservative in our
sample size calculation. Based on an earlier RCT on the
efficacy of CBT and another RCT on the efficacy of par-
oxetine in the treatment of PTSD, we expect to find a
total CAPS score of 23.7 (SD=26.1) in the cognitive be-
havioral group [38] and of 34.8 points (SD=25.7) in the
paroxetine group [15]. Power calculations showed that a
total of 89 participants in each treatment group will be
required to demonstrate a difference of 11.1 points
(alpha=5%, power=80%). To allow for 20% attrition at
follow-up, we will assess 234 patients (N=117 in each
treatment group).
Sample size calculation adjustment
We decided to adjust the sample size calculation and to
optimize the power of the trial given the current study
design, resulting in a smaller but more feasible sample
size, in the light of possible slow recruitment. The ori-
ginal sample size calculation was based on the outcome
on a single follow-up measurement, and was therefore
rather conservative. As repeated measurements during
follow-up provide additional data, differences can be
estimated with higher accuracy, and therefore a smaller
sample size is required to demonstrate a similar
difference.
The increase in power does not solely depend on the
number of measurements, but also on the correlation
between measurements on the same patient (intra class
correlation or ICC). Additional measurements add rela-
tively less information to previous measurements if mea-
surements are highly correlated. The required sample
size for our study was therefore based on the study of
Rochon [39] showing that for five measurements on
each patient, for ICCs from 0 to 0.5, between 36 and 68
patients are required in each arm with an effect size of
Cohen’s d=0.3, while between 14 and 25 patients per
arm are needed with an effect size of 0.5. With an
Polak et al. BMC Psychiatry 2012, 12:166 Page 4 of 11
http://www.biomedcentral.com/1471-244X/12/166anticipated effect size of 0.46 we would need between 20
and 36 (depending on the actual ICC) patients per meas-
urement per arm, respectively to gain a difference of 12
points on the CAPS at 18 months post-treatment. An-
ticipating possible attrition of study participants of 20%,
we aim for 45 patients in each arm for the entire study
period. Our new sample size is in line with another
comparative study on long-term treatment effects of
SSRI versus trauma-focused psychological treatment up
to date that indicates that a smaller sample size may be




Psychotherapy Trauma-Focused Cognitive Behavioral
Therapy (TF-CBT) Participants allocated to the TF-CBT
intervention, will receive 12 weekly sessions with a certi-
fied therapist who strictly follows a clinician manual for
TF-CBT. CBT will be given by therapists who have clin-
ical experience and at least a Master’s degree in Clinical
Psychology or in Medicine and should have followed the
training for TF-CBT at our department, in order to
properly execute the clinician manual. The therapist will
receive supervision regularly (once a month) and all ses-
sions will be tape-recorded.
Trauma-Focused Cognitive Behavioral Therapy (TF-
CBT) will be based on the model originally developed by
Foa for female victims of rape [40]. In TF-CBT exposure
(both in vivo and imaginal exposure) and cognitive re-
structuring (examining and challenging dysfunctional
thoughts) are the most prominent elements next to
psycho-education and anxiety management (e.g. muscle
relaxation or breathing retraining). Subjects will take
part in a structured therapy that follows a strict protocol
developed by Creamer et al. [41] and based on the as-
sumption that mental health specialists should be well-
trained in the use of exposure, and particularly imaginal
exposure. The clinician manual of Creamer is further
developed and adjusted by the research staff of the
current study. The first sessions are devoted to establish-
ing a therapeutic alliance, giving psycho-education, and
teaching relaxation skills and will take 60 minutes. Anx-
iety management strategies may be introduced, which
include physical (i.e. breathing control, relaxation techni-
ques, aerobic exercise, reducing stimulants such as caf-
feine and nicotine), cognitive (i.e. thought stopping,
distraction techniques, imagery) and behavioral inter-
ventions (for addressing other associated problems, such
as sleep disturbance, assertion and communication defi-
cits). Not all strategies need to be provided, but accord-
ing to the specific client several can be selected. In
addition, the theoretical rationale of exposure-based
therapy is introduced and repeated throughouttreatment. Furthermore, the principle of the Subjective
Units of Distress Score (SUDS), a rating system on a
100-point scale ranging from 0 (no anxiety) to 100 (ex-
treme anxiety), is introduced and targets for exposure
are identified. The following sessions imaginal exposure
will be done. During imaginal exposure, the patient
retells the traumatic experience in detail, SUDS are
being registered and “hot spots” identified until anxiety
reduction occurs. Exposure sessions can be accompanied
by cognitive restructuring and focus on identifying, chal-
lenging and replacing maladaptive thought and beliefs
associated with the trauma. The number of exposure
sessions depends on the severity of the distress and the
decrease of anxiety and will be 90 minutes. Homework
assignments include practicing muscle relaxation or
breathing techniques, confronting feared but safe situa-
tions (in vivo exposure), and daily listening to a taped
narrative of the trauma (imaginal exposure). At the final
sessions treatment progress is evaluated and relapse pre-
vention is provided, reviewing the techniques used in
therapy, evaluating their helpfulness, and discussing gen-
eral termination issues. The relapse prevention session
will be 60 minutes.
Each session, the therapist documents mental health
status with the Clinical Global Impression scale. All sub-
jects will be asked to weekly fill out the Impact of Event
Scale-Revised [42].Pharmacotherapy paroxetine (Seroxat) Participants
allocated to the pharmacotherapy intervention will receive
paroxetine (Seroxat). Treatment will be given by certified
psychiatrists according to a manual that is developed and
adjusted by the research staff of this study.
Pharmacotherapy will be in accordance with Dutch
guidelines of pharmacotherapy for anxiety disorders [8]
and the NICE guidelines for clinical excellence [9]. Par-
oxetine treatment will start with psycho-education and
discuss paroxetine intake and possible side effects. Par-
oxetine treatment will be initiated at 20 mg daily for 4
weeks. After 4 weeks the study psychiatrist can increase
the dosage with increments of 10 mg daily each 4 weeks
up to a maximum of 60 mg daily if according to the
judgement of the study psychiatrist, the patient does not
respond to lower dosages and if clinically tolerated. After
24 weeks of treatment the antidepressant will be
gradually discontinued (tapering off in 10 or 20 mg
decrements per week). If discontinuation/withdrawal
symptoms do emerge and are mild, the psychiatrist will
reassure the patient that these symptoms are not un-
common after discontinuing an antidepressant and will
disappear in a few days. If symptoms are severe, reintro-
duction of the original antidepressant and gradual
tapering is required.
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tors for adverse side effects, evaluates compliance with
the Morisky Medication Adherence Scale [43] and
documents mental health status with the Clinical Global
Impression scale. All subjects will be asked to fill out the
Impact of Event Scale-Revised [42]. Every session takes
20–30 minutes. The psychiatrist will be instructed not to
perform any direct psychotherapeutic interventions at
the visits.
Assessments
Assessments will take place pre-intervention (T0), 1
week post-intervention (T1) and 3, 6, 12 and 18 months
at follow-up (T2-T5). Below we will describe the instru-
ments that we will use in more detail.
Clinical assessments
Clinician Administered PTSD Scale (CAPS) is one of the
most widely used structured clinical interviews for diag-
nosing PTSD according to DSM-IV [44] and assessing
PTSD symptom severity [37]. The CAPS distinguishes
between the estimated frequency (range: 0–4) and inten-
sity (range: 0–4) of the various symptoms. Frequency
and intensity scores are added up to a total CAPS score
(range: 0–136). The Dutch translation of the CAPS exhi-
bits adequate validity and reliability. The internal
consistency of this scale is good with alpha .63 for re-ex-
periencing, .78 for avoiding and .79 for hyperarousal and
.89 for all core PTSD symptoms together [45].
Clinical Global Impression scale (CGI) will be used to
assess the response rate by rating the proportion of
responders with a CGI improvement rating of “very
much improved” or “much improved”. The CGI was first
developed for use in psychopharmacology trials as part
of the NIMH collaborative study of schizophrenia [46].
Since then it has been used as a standard primary out-
come measure in studies investigating the efficacy of
pharmacological treatments. Criteria for response will be
a 30% or greater change from baseline on the CAPS and
a final CGI rating of 1 or 2 (“much improved” or “very
much improved”).
M.I.N.I. International Neuropsychiatric Interview-Plus
(M.I.N.I.-Plus) will be used to assess psychopathology
[47]. The M.I.N.I.-Plus is a widely used structured clin-
ical interview that can diagnose past and present DSM-
IV psychiatric disorders, such as mood disorders (i.e.
major depressive, dysthymic or manic disorder), anxiety
disorder (i.e. panic disorder, generalized anxiety disorder
or obsessive compulsive disorder) or substance related
disorders. Every module consists of screening questions
which, if responded positively, will lead to additional
examination for diagnosing the specific disorder. The
M.I.N.I-Plus has reasonable to good interrater reliability
(i.e. .84 for major depressive disorder and .43 for drugdependence). A Dutch translation of the M.I.N.I.-Plus is
available [48].
Self-report assessments
Basic demographic variables, i.e. birth date, sex, marital
status, number of children, origin of parents, highest
level of education, profession, number of working hours
will be assessed.
Trimbos/iMTA questionnaire for Costs associated with
Psychiatric Illness (TiC-P) is used to document resource
utilization to estimate direct (i.e. medical consumption)
and indirect costs (e.g. work absenteeism) associated
with psychiatric illness [49]. Volumes of resource
utilization will be valued by unit costs estimated accord-
ing to the Dutch guideline on (unit) costing in health-
care [50]. GP visits, medical specialist visits, physical
therapists, and travelling will be valued based on the
guideline prices. Psychotherapy sessions will be based
on reported expenses or recommended prices from
the professional associations. Medication costs will be
valued by their market prices [51]. The friction cost
method will be used to estimate the duration of lost
productivity, age adjusted average daily wages will be
used to value this duration.
World Health Organization-Quality of Life Bref
(WHOQOL) assesses quality of life [52]. The WHOQOL
is a 26-item questionnaire to measure quality of life, in-
cluding physical health, psychological health, social rela-
tionships and environment. Items are scored on 5-point
scales from 1 (worse outcome) to 5 (best outcome) with
a total range from 4–20. The Dutch version has demon-
strated good content validity, construct validity and
reliability [53].
Euroqol 6-Dimensions scale (EQ-6D) is an easy to
apply self-administered questionnaire for describing and
valuing quality of life [54] and can be used to generate
cross-national comparisons of health state. The first part
measures five health dimensions: mobility (MO), self-
care (SC), daily activities (DA), pain/discomfort (PD),
mood (MD) consisting of both anxiety and depression
and cognitions (CD). In the EQ-6D patients report: 0
(no problems), 1 (moderate problems), and 2 (extreme
problems). The second part (EQ-VAS) is a thermometer-
like scale, in which patients rate their overall wellbeing
from 0 (worst imaginable overall health) to 100 (best im-
aginable overall health). It originated from the ED-5D
[55] that is shown to be valid and frequently used to as-
sess generic quality of life and health status [56].
Treatment preference will be assessed by a question
concerning of the preferred treatment if they would have
had a choice. Preferred treatment can be indicated as:
‘TF-CBT’, ‘paroxetine’ or ‘no preference’.
Hospital Anxiety and Depression Scale (HADS) will be
used to assess the level of depression and anxiety
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taining two subscales: HADS-A (Anxiety, 7 items, range:
0–21) and HADS-D (Depression, 7 items; range: 0–21).
The HADS is validated in Dutch and showed satisfactory
test-retest reliability for both subscale scores (Pearson’s
r’s = .89 and .86 respectively) and validity [58].
Life Events Checklist (LEC) is a semi-structured inter-
view that will be assessed to record the number and se-
verity of the trauma(s) [59].
Impact of Event Scale-Revised (IES-R) is a question-
naire to assess the level of trauma reactions in the pre-
ceding 7 days that are associated with a traumatic event
[42]. The IES-R contains 22 items (with 5-point Likert
scales, 0–4) and three subscales, corresponding to the
three symptom clusters in the DSM-IV PTSD diagnosis:
re-experiencing (8 items, scale range 0–32), avoidance (8
items, range 0–32) and hyperarousal (6 items, range 0–
24). The IES-R has been translated in Dutch and vali-
dated [60].
Smoking screen Standard Questionnaire Smoking
(‘Standaardvraagstelling Roken’) is a questionnaire con-
taining two questions that assess smoking habits. These
questions have been used primarily by Dutch health
organizations (GGD) to indicate smoking habits in eld-
erly patients but are currently used to indicate smoking
habits according to frequency and the variability
(i.e. cigars, cigarettes) in other groups as well.
Alcohol Use Disorders Identification Test (AUDIT) was
developed by the World Health Organization (WHO)
in 1982 and is a screening instrument that assesses
excessive drinking patterns and consists of 10 ques-
tions concerning recent alcohol use, alcohol dependence
symptoms and alcohol-related problems [61]. This in-
strument is validated and designed for international use
and cross-nationally standardized. The AUDIT identifies
alcohol use as well as possible dependence, is brief, rapid
and flexible and is consistent with the ICD-10 defini-
tions of alcohol dependence and harmful alcohol use.
Moreover, in several studies high validity as well as high
reliability was found.
Subjective Health Complaints Inventory (SHC) is a 29-
item scale that registers occurrence, intensity, and dur-
ation of subjective somatic and psychological complaints
experienced during the past 30 days, without reference
to specific diagnostic categories [62,63]. The intensity of
each complaint graded on a 4-point scale (not at all/lit-
tle/some/severe). An SHC total score is created by add-
ing the scores of each item on somatic and psychological
complaints. It records ailments based on objective dis-
eases, but is particularly sensitive to health complaints
with minimal or no clinical findings. The instrument can
be divided into five categories: musculoskeletal pain,
pseudo neurology, gastrointestinal problems, allergy and
flu. The scores for each item range from 0 to 3, giving atotal score from 0 (excellent) to 87 (very poor). The
questionnaire has satisfactory validity and reliability.
Morisky Medication Adherence Scale (MMAS) is a
self-reported measure of medication taking developed
from a previously validated 4-item scale and supplemen-
ted with additional items addressing the circumstances
surrounding adherence behavior [42].Procedure
All patients referred to the outpatient psychiatric clinic at
the AMC will receive a diagnostic medical intake proced-
ure, in which psychiatric and medical history are exam-
ined. In case PTSD diagnosis is suspected, the intake
procedure will consist of standardized diagnostic mea-
sures for PTSD and other DSM-IV diagnoses (CAPS and
M.I.N.I.-Plus). If PTSD is confirmed and all inclusion cri-
teria are met, the patient will be requested to participate
in the study. After giving informed consent, a baseline as-
sessment (T0) will be performed. This assessment will
consist of self-reported symptoms of PTSD, depression
and anxiety and questionnaires on quality of life and
costs. Subsequently, patients will be randomized to either
TF-CBT or paroxetine treatment. One week after treat-
ment, another assessment will be done (T1), consisting
of the same questionnaires. At 3 months (T2), 6
months (T3), 12 months (T4) and 18 months (T5)
assessments will be repeated. Figure 1 shows a flow-
chart of the study. Table 1 explores an overview on all
instruments being assessed.
Statistical analyses
All analyses will be performed according to the
intention-to-treat (ITT) principle. Patients will be
classified as responders and non-responders to treat-
ment. Criteria for treatment response will be a 30%
or greater change from baseline on the CAPS and a
final CGI rating of 1 or 2 (“much improved” or “very
much improved”).
Patients will also be classified in terms of compliance
with the treatment regime and completion of the treat-
ment and study procedures. Completers are those
patients who finished the study scheme and who were
available for at least one post-intervention assessment.
Compliance concerns the adherence of treatment proto-
col, i.e. taking medication. Non-compliant patients are
those patients who failed to take their medications or
who failed to adhere to the TF-CBT sessions for >25% of
the time. Regarding drop-out and loss to follow-up, a
careful procedure will be followed in order to avoid an
early exclusion of non-completers. Furthermore, ad-
equate methods for imputation of missing data will be
used, such as Maximum Likelihood Estimation (MLE) or
Multiple Imputation method (MI).
No study inclusion
In and exclusion














1 week 3 months 6 months 12 months 18 months
Intake at AMC out-
patient clinic
Figure 1 Flowchart.
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ences in demographic, trauma-related characteristics at
baseline between the TF-CBT group and the paroxetine
group. Continuous CAPS scores at post-intervention
assessments will be compared using analysis of covari-
ance with study treatment (SSRI or TF-CBT) as mainTable 1 Overview of instruments per assessment time point





CGI X X X








IES-R X X X




CAPS: Clinician Administered Posttraumatic Stress Disorder Scale (Blake et al., 1995)
International Neuropsychiatric Interview-Plus (Sheehan et al., 1998); TiC-P: Trimbos/i
Roijen et al., 2002); WHOQOL: World Health Organization Quality of Life (WHOQOL G
Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983); LEC: Life of Events
Alcohol Use Disorders Identification Test; SHC: Social Health Complaints Inventory (U
Scale (Morisky et al., 2008).effect, adjusting for differences at baseline and other po-
tential confounders (i.e. gender, age). Differences be-
tween both treatment groups will be evaluated by
analysis of repeated measures, using linear mixed mod-
els. In multivariate analyses we will adjust the estimated








X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
; CGI: Clinical Global Impression scale (Guy, 1976); M.I.N.I.-Plus: MINI
MTA questionnaire for Costs associated with Psychiatric illness (Hakkaart-Van
ROUP, 1998); EQ-6D: Euoqol 6-Dimensions (Hoeymans et al., 2005); HADS:
Checklist; IES-R: Impact of Event Scale-Revised (Weiss & Marmar, 1997); AUDIT:
rsin et al., 1988; Eriksen et al., 1999); MMAS: Morisky Medication Adherence
Polak et al. BMC Psychiatry 2012, 12:166 Page 8 of 11
http://www.biomedcentral.com/1471-244X/12/166gender, age, SES, co-existence of a moderate depression).
Regarding drop-out and loss to follow-up, different
analytical approaches (complete case analysis, last
observation carried forward, multiple imputation, best/
worst outcome) will be followed in order to assess their
impact on the study results. All analyses will be per-
formed using SPSS 18.0.
Subgroup analyses
Several subgroup comparisons are of interest. Because of
the power of the current proposal it will, however, not
be possible to establish potential interaction effects or
differential effects with statistical certainty. Therefore
subgroup comparisons will have a hypothesis generating
function. Since certain types of trauma and PTSD are
more prevalent in females, non-whites, persons with low
socio-economic status and in early adulthood (i.e., 18–
22) [64], three more post-hoc analyses will be performed
to examine the comparative effectiveness of both CBT
and paroxetine in 1) men and women, 2) different age
groups and 3) low and high socio-economic status.
Economic evaluation
The economic evaluation will be performed from a soci-
etal perspective, with the costs per unit improvement on
the primary outcome (CAPS score) as the primary out-
come measure. The appropriate type of economic evalu-
ation is conditional on the results [65]. We hypothesize
that a more effective intervention will be associated with
less health care utilization as well as less burden to rela-
tives (time costs) and absence from paid work (product-
ivity costs). Therefore, the primary analysis in the
economic evaluation will be a cost-effectiveness analysis
that evaluates costs associated with an improved PTSD
outcome in terms of CAPS scores. In addition, a second-
ary analysis will evaluate cost differences in relation to
differences in quality-adjusted life years (QALYs). This
cost-utility analysis, resulting in an incremental cost-
effectiveness ratio expressed in costs per QALY, will be
included to allow comparison with other health-related
interventions or programs. With a study horizon of 18
months, no discounting will be applied.
We will differentiate between direct medical, direct
non-medical and indirect costs. Direct medical costs are
associated with health care utilization related to the
pharmacological or psychological treatment, as well as
to inpatient and outpatient mental health care, day-
treatment and primary physician care. Direct non-
medical costs are generated by travel to and from health
care providers. Indirect costs are associated with lost
productivity due to absence from paid work.
Health state utilities to estimate QALYs will be derived
from an EQ-6D measurement at baseline, as well as the
follow-up assessments. Utility values for EQ-6D scoreswill be based on UK-estimates [53]. Utility scores will be
uniformly interpolated, assuming constant health state
between subsequent assessments.
Robustness of the results for uncertainty in the
assumptions will be evaluated in sensitivity analyses, in-
cluding: Dutch health states [66] and a linear
interpolation between EQ-6D measurements, varying
unit costs for pertinent volumes of health care
utilization (e.g. therapy costs, productivity costs). In
model-based analyses using data from literature about
these middle to long-term effects and costs associated
with PTSD patients we will extrapolate the results to es-
timate the effectiveness and cost-effectiveness for both
treatment options on long term (3–5 years).
Discussion
This RCT represents a unique study that aims to directly
compare the most commonly used psychological inter-
vention (TF-CBT) and pharmacological intervention
(paroxetine) on (cost-) effectiveness in PTSD patients on
the short and the long term. Although there is ample
evidence that both treatments are effective, a systematic
head to head comparison on the short term and espe-
cially on the long term is lacking. Thus far, only a hand-
ful of studies have compared pharmacological and
psychological treatments directly [11,28] and there is un-
certainty on the comparative longer term effectiveness
and cost-effectiveness of these treatments.
Gaining insight in effectiveness of treatment in terms
of reduction of PTSD symptoms will reduce significant
personal suffering and help to reduce societal costs
(i.e. regain of productivity and reduce sick leave) not
only during treatment but also on the long term.
Strengths and limitations
A particular strength of the study is that it is unique in
comparing a pharmacological treatment with psycho-
logical treatments on the short and the long term. Its
sample size is sufficient to differentiate the treatment in
effectiveness and cost-effectiveness over the short and
the long term, where at present only studies are available
that did not take into account long-term effects [11,28].
Some limitations may affect the trial that need to be
considered. Firstly, even though we aimed to reduce dif-
ferent influencing factors between pharmacological fac-
tors and psychological factors, this is rather difficult as
the nature of the two treatments differs. Regarding this
difference, the two treatments vary in duration as well as
in number and length of the sessions, with pharmaco-
logical treatment approximately 24 weeks and psycho-
logical treatment consisting of approximately 12 weekly
sessions. As we already outlined previously, the length of
pharmacological treatment is very essential with possible
high relapse rates during short-term treatments [29,31].
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the protocols as much as possible; both protocols consist
of comparable psycho-education as well as a relapse pre-
vention session. Furthermore, questionnaires will be per-
formed in the same order in both treatment protocols.
Other differences intertwined in the nature of both
treatments should not be eliminated since the compari-
son of both treatments should be based on conditions
that reflect routine clinical practice in this pragmatic ef-
fectiveness trial.
Another possible limitation may lie in the fact that we
only include PTSD patients that are able to receive
monotherapy with either TF-CBT or paroxetine. Some
patients may not be eligible for exposure or monother-
apy with pharmacotherapy due to a variety of reasons,
such as the presence of primary severe depressive dis-
order or suicidal ideation, other comorbid disorders
(i.e. personality disorders) and severe psychosocial pro-
blems that may interfere with treatment. Patients with
more severe PTSD symptoms are often recommended
combination therapy with both pharmacotherapy and
psychotherapy [33]. A recent meta-analysis [67] compar-
ing the effectiveness of combination therapies with the
separately delivered interventions, could however not
draw clear conclusions due to lack of evidence and
urged for large randomized controlled trials. Despite the
fact that combination therapies are common, and direct
comparison leads to exclusion of patients with more
complex symptoms, we nonetheless think it is very im-
portant to first carefully investigate the relative superior-
ity of one treatment to another. By directly comparing
these separate treatments we will be able to draw solid
conclusions on (cost-) effectiveness.Implications for practice
Clinicians’ decisions about optimal care, and the clinical
practice guidelines that inform these decisions, will
of course rely to a large extent on evidence from
adequate RCTs. For example, recently, a growing num-
ber of studies on the effectiveness of Eye Movement
Desensitization and Reprocessing (EMDR) have been
conducted (i.e. [10]) as well as meta-analyses (i.e. [34])
and reviews (i.e. [68]), comparing results across RCTs on
EMDR and other treatments, showing that EMDR is
equally effective as TF-CBT (see also Nijdam et al. [12]).
This finding led to recommendation and implementation
of EMDR as a first-line psychological treatment besides
TF-CBT. Likewise, evidence on the direct comparison of
effective psychological and pharmacological interven-
tions regarding (cost-) effectiveness is scarce and this
RCT may help answering questions concerning the most
optimal care. If our premise that TF-CBT is superior to
paroxetine in terms of sustainable effectiveness and cost-effectiveness for the treatment of PTSD, this could have
major implications for current clinical practice.
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